Charles River Laboratories International, Inc. $CRL Stock Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Charles River Laboratories position by 230.9% in the third quarter, adding 142,716 shares to own 204,537 shares valued at approximately $59 million. Institutional investors collectively own 98.91% of the company.
• Charles River reported quarterly EPS of $3.02, exceeding the $2.77 analyst consensus, while revenue reached $1 billion but declined 2.7% year over year. Management guided to fiscal 2026 EPS of $11.15–$11.45.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $302.33; however, company insiders sold 91,971 shares worth about $26 million during the latest quarter.

Assenagon Asset Management S.A. lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 230.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,537 shares of the medical research company's stock after buying an additional 142,716 shares during the period. Assenagon Asset Management S.A. owned about 0.43% of Charles River Laboratories International worth $59,044,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Continuum Advisory LLC bought a new stake in Charles River Laboratories International in the 2nd quarter valued at $30,000. SHP Wealth Management acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $85,000. Trust Asset Management LLC acquired a new position in shares of Charles River Laboratories International during the second quarter worth about $129,000. Hilltop National Bank boosted its position in shares of Charles River Laboratories International by 28.7% during the second quarter. Hilltop National Bank now owns 569 shares of the medical research company's stock worth $129,000 after buying an additional 127 shares during the period. Finally, Mather Group LLC. grew its holdings in shares of Charles River Laboratories International by 657.7% during the third quarter. Mather Group LLC. now owns 591 shares of the medical research company's stock worth $174,000 after buying an additional 513 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $300.35 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $333.30. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The firm has a fifty day simple moving average of $289.50 and a 200 day simple moving average of $227.68. The stock has a market capitalization of $14.34 billion, a PE ratio of -61.93, a P/E/G ratio of 2.80 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CRL shares. Evercore set a $330.00 target price on Charles River Laboratories International in a research report on Friday, September 25th. Morgan Stanley upped their price target on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an "overweight" rating in a research report on Monday, October 12th. Royal Bank Of Canada raised their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Robert W. Baird lifted their price objective on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a report on Friday, September 25th. Finally, Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $302.33.

Insider Activity at Charles River Laboratories International

In other news, Director Nancy C. Andrews sold 573 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director owned 1,438 shares in the company, valued at approximately $410,175.12. This trade represents a 28.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James C. Foster sold 33,561 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the sale, the director directly owned 31,596 shares of the company's stock, valued at $9,478,800. The trade was a 51.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 91,971 shares of company stock worth $26,033,968 in the last quarter. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.